WuXi AppTec Co Ltd
SSE:603259

Watchlist Manager
WuXi AppTec Co Ltd Logo
WuXi AppTec Co Ltd
SSE:603259
Watchlist
Price: 49.63 CNY -5.59% Market Closed
Market Cap: 124.1B CNY
Have any thoughts about
WuXi AppTec Co Ltd?
Write Note

WuXi AppTec Co Ltd
Net Issuance of Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

WuXi AppTec Co Ltd
Net Issuance of Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Issuance of Debt CAGR 3Y CAGR 5Y CAGR 10Y
WuXi AppTec Co Ltd
SSE:603259
Net Issuance of Debt
ÂĄ1.3B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Pharmaron Beijing Co Ltd
SZSE:300759
Net Issuance of Debt
-ÂĄ301.7m
CAGR 3-Years
N/A
CAGR 5-Years
-17%
CAGR 10-Years
N/A
WuXi Biologics (Cayman) Inc
HKEX:2269
Net Issuance of Debt
-ÂĄ765.3m
CAGR 3-Years
N/A
CAGR 5-Years
-144%
CAGR 10-Years
N/A
Hangzhou Tigermed Consulting Co Ltd
SZSE:300347
Net Issuance of Debt
ÂĄ529.9m
CAGR 3-Years
20%
CAGR 5-Years
20%
CAGR 10-Years
13%
M
MGI Tech Co Ltd
SSE:688114
Net Issuance of Debt
ÂĄ249.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
W
WuXi XDC Cayman Inc
HKEX:2268
Net Issuance of Debt
-ÂĄ75.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

WuXi AppTec Co Ltd
Glance View

Market Cap
124.1B CNY
Industry
Life Sciences Tools & Services

WuXi AppTec Co., Ltd. is a prominent global healthcare platform that plays a pivotal role in empowering the pharmaceutical, biotechnology, and medical device industries. Founded in 2000 and headquartered in Shanghai, WuXi has cultivated a reputation for excellence through its extensive suite of services, which span the entire drug development lifecycle. From drug discovery to manufacturing, the company leverages cutting-edge technologies and a rich network of expertise to facilitate the development of innovative therapeutics. This comprehensive capability enables WuXi to serve as a trusted partner for clients, helping to streamline the complex path from concept to commercialization. With a focus on innovation and quality, WuXi AppTec has distinguished itself in the competitive landscape of contract research organizations (CROs) and contract manufacturing organizations (CMOs). The company's robust growth trajectory is underpinned by strategic investments in technology and infrastructure, as well as a commitment to expanding its global footprint. WuXi's expansive service offerings not only enhance operational efficiency for its partners but also align with the increasing demand for faster and more cost-effective drug development solutions. For investors, WuXi signifies an opportunity to engage with a market leader poised to capitalize on the burgeoning biopharmaceutical sector, driven by rising global healthcare needs and transformative advancements in science and technology.

Intrinsic Value
88.5 CNY
Undervaluation 44%
Intrinsic Value
Price

See Also

What is WuXi AppTec Co Ltd's Net Issuance of Debt?
Net Issuance of Debt
1.3B CNY

Based on the financial report for Jun 30, 2024, WuXi AppTec Co Ltd's Net Issuance of Debt amounts to 1.3B CNY.

What is WuXi AppTec Co Ltd's Net Issuance of Debt growth rate?
Net Issuance of Debt CAGR 1Y
-3%

Over the last year, the Net Issuance of Debt growth was -3%.

Back to Top